

MMAD

Catalog No: tcsc1613



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

203849-91-6

Formula:

$C_{41}H_{66}N_6O_6S$

Pathway:

Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related

Target:

Microtubule/Tubulin;Microtubule/Tubulin;ADC Cytotoxin

Purity / Grade:

>98%

Solubility:

DMSO : 24.5 mg/mL (31.77 mM; Need ultrasonic and warming)

Alternative Names:

Demethyldolastatin 10;Monomethylauristatin D;Monomethyl Dolastatin 10

Observed Molecular Weight:

771.06


Product Description

MMAD is a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugates (**ADCs**).

IC50 & Target: Tubulin^[1]

In Vitro: MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity^[1].

In Vivo: The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!